HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stefan Höcht Selected Research

Prostatic Neoplasms (Prostate Cancer)

3/2023[Ultrahpyofractionated radiotherapy for prostate cancer-a new standard?]
1/2023Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus.
1/2022Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases.
1/2022German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
11/2021Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
10/2021Timing of ADT in Radiotherapy of Prostate Cancer.
1/2021Postoperative radiotherapy in prostate cancer.
1/2021Radiotherapy in nodal oligorecurrent prostate cancer.
7/2020Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
2/2020Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stefan Höcht Research Topics

Disease

20Prostatic Neoplasms (Prostate Cancer)
03/2023 - 03/2002
10Neoplasms (Cancer)
01/2022 - 01/2004
4Neoplasm Metastasis (Metastasis)
01/2022 - 04/2005
3Endometrial Neoplasms (Endometrial Cancer)
08/2023 - 10/2018
3Rectal Neoplasms (Rectal Cancer)
03/2008 - 11/2003
3Melanoma (Melanoma, Malignant)
12/2005 - 01/2004
2Hemangioma (Angioma)
10/2006 - 01/2004
2Uveal melanoma
12/2005 - 07/2004
1Esophageal Neoplasms (Esophageal Cancer)
12/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2021
1Lymphatic Metastasis
05/2021
1Lung Neoplasms (Lung Cancer)
05/2021
1Mastodynia
07/2020
1Gynecomastia
07/2020
1Carcinosarcoma
11/2018
1Margins of Excision
01/2018
1Brain Neoplasms (Brain Tumor)
04/2005
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2004
1Eye Neoplasms (Eye Cancer)
01/2004
1Keratitis
02/2002

Drug/Important Bio-Agent (IBA)

4AndrogensIBA
01/2021 - 01/2018
4Protons (Proton)IBA
10/2006 - 01/2004
2Hormones (Hormone)IBA
01/2022 - 01/2021
1Androgen Antagonists (Antiandrogens)IBA
07/2020
1Anastrozole (Arimidex)FDA LinkGeneric
07/2020
1Prostate-Specific Antigen (Semenogelase)IBA
01/2003
1StrontiumIBA
02/2002

Therapy/Procedure

25Radiotherapy
08/2023 - 03/2002
13Therapeutics
08/2023 - 12/2005
4Drug Therapy (Chemotherapy)
08/2023 - 11/2003
4Adjuvant Radiotherapy
11/2018 - 03/2002
3Chemoradiotherapy
12/2021 - 01/2004
3Prostatectomy (Retropubic Prostatectomy)
01/2018 - 01/2003
3Proton Therapy
10/2006 - 01/2004
2Proctectomy
03/2004 - 01/2004
1Off-Label Use
07/2020
1Palliative Care (Palliative Therapy)
11/2018
1Aftercare (After-Treatment)
11/2018
1Neoadjuvant Therapy
03/2008
1Cyclotrons
01/2004